Elisa de Stanchina

Facility Head

Office Phone


Office Fax


Lab Phone





Manchado E, et al. (2016) “A combination strategy for treating KRAS mutant lung cancer”. Nature 534:647-51

Rodrik-Outmezguine VS, et al (2016). “Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor”. Nature 534:272-6

Malladi S, et al. (2016).  “Metastatic Latency and Immune Evasion Mediated by Autocrine DKK1”. Cell 165:45-60

Fattahi F, et al. (2016). “Pluripotent-derived human enteric neuron lineage for combined cell and drug-based therapy in Hirschsprung’s disease”. Nature 531:105-9

LaFave LM, et al. (2015) “Loss of BAP1 function leads to EZH2-dependent transformation”. Nat Med 21:1344-9

Yao Z, et al. (2015). “BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to drugs.” Cancer Cell 28:370-83

Shih AH, et al. (2015). “Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia”. Cancer Cell 27:502-15

Maddalo D, et al. (2014). “In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system”. Nature 516: 423-7.

Schwartz S, et al. (2014). Feedback suppression of PI3Kα signaling in PTEN negative tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell  27:109-22.

Lovly CM, et al. (2014). “Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.” Nat Med. 20:1027-34

Huang CH, et al. (2014). “CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma”. Genes Dev. 15:1800-14

Wolfe A, et al. (2014). “RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer”. Nature 513: 65-70 PMID: 25079319

Clohessy JG and de Stanchina E (2013). “Infrastructure needs for translational integration of mouse and human trials”. Mouse Models of Cancer, CSHL Press: 461-66.

Piovan E, et al. (2013). “Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia”. Cancer Cell 24:766-76

Lito P, et al. (2012). “Relief of profound feedback inhibition of mitogenic signaling by Raf inhibitors attenuates their activities in BRAFV600E melanomas”. Cancer Cell 22:668-82

Zammarchi F, et al. (2011). “Anti-tumorigenic potential of STAT3 alternative splicing modulation”. Proc. Natl. Acad. Sci.USA 108-17779-84

Real PJ, et al. (2009). “Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL”. Nature Med. 15: 50-58.